Joe Hirman

3.3k total citations · 3 hit papers
53 papers, 1.8k citations indexed

About

Joe Hirman is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Joe Hirman has authored 53 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Psychiatry and Mental health, 26 papers in Pathology and Forensic Medicine and 16 papers in Physiology. Recurrent topics in Joe Hirman's work include Migraine and Headache Studies (48 papers), Trigeminal Neuralgia and Treatments (22 papers) and Sympathectomy and Hyperhidrosis Treatments (13 papers). Joe Hirman is often cited by papers focused on Migraine and Headache Studies (48 papers), Trigeminal Neuralgia and Treatments (22 papers) and Sympathectomy and Hyperhidrosis Treatments (13 papers). Joe Hirman collaborates with scholars based in United States, Denmark and Germany. Joe Hirman's co-authors include Roger Cady, Jeff Smith, Barbara Schaeffler, Richard B. Lipton, David M. Biondi, Susan Pederson, Brent Allan, Peter J. Goadsby, David W. Dodick and Messoud Ashina and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and The Lancet Neurology.

In The Last Decade

Joe Hirman

52 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

2014 299 citations David W. Dodick, Peter J. Goadsby et al. The Lancet Neurology profile →
Efficacy and safety of eptinezumab in patients with chronic migraine

2020 273 citations Richard B. Lipton, Peter J. Goadsby et al. Neurology profile →
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

2020 264 citations Messoud Ashina, Roger Cady et al. Cephalalgia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joe Hirman United States	18	1.5k	1.1k	675	134	131	53	1.8k
Shazia Afridi United Kingdom	16	1.2k 0.8×	841 0.8×	549 0.8×	176 1.3×	322 2.5×	32	1.8k
David Kudrow United States	26	2.5k 1.7×	1.8k 1.6×	1.1k 1.6×	298 2.2×	275 2.1×	65	2.8k
Ernesto Aycardi United States	14	1.2k 0.8×	846 0.8×	509 0.8×	136 1.0×	108 0.8×	32	1.4k
Mehmet Zarifoğlu Türkiye	21	788 0.5×	425 0.4×	281 0.4×	86 0.6×	237 1.8×	55	1.2k
Melissa Grozinski‐Wolff United States	5	1.2k 0.8×	808 0.7×	465 0.7×	123 0.9×	116 0.9×	7	1.2k
Andrea Alberti Italy	18	575 0.4×	201 0.2×	315 0.5×	130 1.0×	218 1.7×	63	1.4k
Michail Vikelis Greece	17	648 0.4×	388 0.4×	274 0.4×	148 1.1×	158 1.2×	63	977
Eloísa Rubio‐Beltrán Netherlands	17	784 0.5×	422 0.4×	279 0.4×	118 0.9×	124 0.9×	35	1.1k
Lars Neeb Germany	26	1.3k 0.8×	667 0.6×	480 0.7×	226 1.7×	151 1.2×	72	1.7k
Ruozhuo Liu China	19	833 0.6×	437 0.4×	279 0.4×	111 0.8×	189 1.4×	71	1.2k

Countries citing papers authored by Joe Hirman

Since Specialization

Citations

This map shows the geographic impact of Joe Hirman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joe Hirman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joe Hirman more than expected).

Fields of papers citing papers by Joe Hirman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joe Hirman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joe Hirman. The network helps show where Joe Hirman may publish in the future.

Co-authorship network of co-authors of Joe Hirman

This figure shows the co-authorship network connecting the top 25 collaborators of Joe Hirman. A scholar is included among the top collaborators of Joe Hirman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joe Hirman. Joe Hirman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Porreca, Frank, Edita Navratilova, Joe Hirman, et al.. (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia. 44(3). 2225283209–2225283209. 22 indexed citations

Starling, Amaal J., Robert P. Cowan, Dawn C. Buse, et al.. (2023). Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized PROMISE ‐2 trial. Headache The Journal of Head and Face Pain. 63(2). 264–274. 9 indexed citations

Cowan, Robert P., Michael J. Marmura, Hans‐Christoph Diener, et al.. (2022). Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. The Journal of Headache and Pain. 23(1). 115–115. 2 indexed citations

Lipton, Richard B., Larry Charleston, Cristina Tassorelli, et al.. (2022). Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials. The Journal of Headache and Pain. 23(1). 23–23. 6 indexed citations

Martin, Vincent T., Marina Janelidze, Joe Hirman, et al.. (2022). Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. Clinical Therapeutics. 44(3). 389–402. 13 indexed citations

Hirman, Joe, et al.. (2022). Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2. The Journal of Headache and Pain. 23(1). 48–48. 9 indexed citations

Smith, Timothy R., Egilius L.H. Spierings, Roger Cady, et al.. (2021). Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. The Journal of Headache and Pain. 22(1). 16–16. 34 indexed citations

Smith, Timothy R., et al.. (2021). Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. The Journal of Headache and Pain. 22(1). 143–143. 10 indexed citations

Lipton, Richard B., David W. Dodick, Jessica Ailani, et al.. (2020). Patient-Identified Most Bothersome Symptom in Patients with Chronic Migraine: An Analysis of PROMISE-2 (541). Neurology. 94(15_supplement). 1 indexed citations

10.

Silberstein, Stephen D., Merle L. Diamond, Nada Hindiyeh, et al.. (2020). Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study. The Journal of Headache and Pain. 21(1). 120–120. 72 indexed citations

11.

Ailani, Jessica, et al.. (2020). PND102 CORRELATION ANALYSIS OF THE CHANGE IN THREE SF-36 DOMAINS WITH CHANGE IN PATIENT-IDENTIFIED MOST BOTHERSOME SYMPTOM AND MONTHLY MIGRAINE DAYS IN PATIENTS WITH CHRONIC MIGRAINE: RESULTS OF THE PROMISE-2 STUDY. Value in Health. 23. S279–S279. 1 indexed citations

12.

Lipton, Richard B., Peter J. Goadsby, Jeff Smith, et al.. (2020). Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 94(13). e1365–e1377. 273 indexed citations breakdown →

13.

Dodick, David W., Timothy R. Smith, Roger Cady, et al.. (2019). Eptinezumab Demonstrates Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials (S17.004). Neurology. 92(15_supplement). 3 indexed citations

14.

Lipton, Richard B., et al.. (2019). PND81 PATIENT GLOBAL IMPRESSION OF CHANGE RELATED TO IMPROVEMENT IN MOST BOTHERSOME SYMPTOM FOLLOWING TREATMENT WITH EPTINEZUMAB. Value in Health. 22. S285–S285. 1 indexed citations

15.

Lipton, R.B., et al.. (2019). PND82 IMPACT OF EPTINEZUMAB ON THE HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE: SF-36 ANALYSIS BY MONTHS 1 AND 3 ACROSS THE SPECTRUM OF MIGRAINE. Value in Health. 22. S285–S285. 3 indexed citations

16.

Tepper, Stewart J., et al.. (2019). PND80 RAPID MIGRAINE RESPONSE BY MONTH 1 AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MIGRAINE IN PHASE 3 TRIALS OF EPTINEZUMAB. Value in Health. 22. S285–S285. 1 indexed citations

17.

Ständer, Sonja, Paul Kwon, Joe Hirman, et al.. (2019). Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. Journal of the American Academy of Dermatology. 80(5). 1395–1402. 89 indexed citations

18.

Dodick, David W., Peter J. Goadsby, Stephen D. Silberstein, et al.. (2017). Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine. (S52.003). Neurology. 88(16_supplement). 9 indexed citations

19.

Dodick, David W., Peter J. Goadsby, Stephen D. Silberstein, et al.. (2014). Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. The Lancet Neurology. 13(11). 1100–1107. 299 indexed citations breakdown →

20.

Morimoto, Bruce H., et al.. (2013). A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders. 35(5-6). 325–339. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact